Skip to Content
About Abbott
Contact
United States | eng
Country Language
CARDIOVASCULAR
United States | eng
Country Language

Esprit™ BTK

Everolimus Eluting Resorbable Scaffold

Esprit BTK

Take a Stand Against CLTI for Your Patients

Choose the new standard of care for BTK treatment that delivers superior results without compromising safety.


Chronic Limb-Threatening Ischemia (CLTI) is a severe form of peripheral artery disease (PAD) that can lead to amputation and increased mortality/cardiovascular events.1  Now, Abbott's Esprit™ BTK System offers a breakthrough innovation for you and your patients as the first-and-only FDA-approved drug-eluting resorbable scaffold for CLTI. With reduced restenosis and reinterventions,3,6,7 and significant improvement in primary patency and limb salvage,3,6 you can be confident you're giving your patients the state-of-the-art standard of care.

Interested to learn more?

Back to top

Deliver superior results for your patients without compromising their safety

"The durability of this result has never been demonstrated with any BTK technology previously."

-Sahil Parikh, MD, New York-Presbyterian/Columbia University Irving Medical Center

48% Fewer Patients Require Reintervention6,7

  • Esprit™ BTK System patients have 48% fewer reinterventions vs. PTA at 2 years (9.7% vs 18.6%)
  • 90.3% of Esprit™ BTK patients did not require a reintervention through 2 years
Fewer patients require reintervention

Superior Efficacy, Sustained Benefits through 2 Years3,6

  • 31% improvement (74.5% vs. 43.7%) in limb salvage and primary patency at 1 year, with sustained benefits through 2 years
  • Demonstrated to be as safe as PTA at 2 years in the LIFE-BTK study
Superior efficacy sustained through 2 years

Proven Primary Treatment6

  • Addresses vessel recoil and dissection4, with radial strength similar to a metallic stent within the first 6 months8
  • Inhibits restenosis and maximizes patency through sustained everolimus elution5
  • Preserves flexibility for the future with complete resorption9
Proven primary treatment
Learn More About the LIFE-BTK Study
BTK technology

The LIFE-BTK Study, published in the New England Journal of Medicine, is the first successful RCT to demonstrate superiority of an interventional device over standard of care for treatment of BTK disease in CLTI patients. The 2-year data demonstrated sustained efficacy and safety.3,6

Life BTK study

Back to top

Life btk study
Life btk study

Take BTK Treatment in Stride with State-of-the-Art Care

Watch how the Esprit™ BTK System does it all for CLTI: addressing vessel recoil and dissection,4 combined with a drug to inhibit neointimal hyperplasia,5 and then fully resorbs over time,9 preserving future treatment options.

Learn More

Back to top

Case Studies: A Giant Step Forward in BTK Treatment

Physicians share their experience with the Esprit™ BTK System and the advantages it delivers in treating their patients and improving outcomes.

Esprit BTK is a new paradigm for limb salvage intervention, creating opportunities for sustained patency and increased pedal perfusion pressure to heal the wound after the first intervention. - Matthew C. Bunte, MD., MS
Esprit BTK is fundamentally changing how I treat my patients with tibial disease - finally we have a tool that offers our patients hope and substantially better outcomes. - J.D. Corl, MD
Read Case Studies

Back to top

Reimbursement: Summary for BTK Revascularization

The coding and reimbursement guide listed below is applicable to lower extremity endovascular procedures in the tibial/peroneal arteries using the Esprit™ BTK Ssytem. Esprit™ BTK can be performed in the hospital inpatient, hospital outpatient, ASC, and office-based labs (OBL) settings.

Hospital inpatient rates are applicable for Sept. 30, 2024 - Oct. 1, 2025. Hospital outpatient, ASC, and OBL rates are applicable for Jan. 1 - Dec. 31, 2025.

 

Hospital Inpatient10 BTK Procedures

MS-DRGDESCRIPTIONFY 2025 MEDICARE NAT'L RATE
BTK STENTING
252Other vascular procedures w/ MCC$24,413
253Other vascular procedures w/ CC$18,169
254Other vascular procedures without CC/MCC$12,450
BTK ATHERECTOMY
270Other major cardiovascular services w/ MCC$36,530
271Other major cardiovascular services w/ CC$24,514
272Other major cardiovascular services without CC/MCC$17,807

 

Hospital Outpatient11 BTK Procedures

APCDESCRIPTION2025 MEDICARE NAT'L RATE
5193Level 3 Endovascular Procedures
  • Angioplasty
$11,341
5194Level 4 Endovascular Procedures
  • Atherectomy
  • Stenting
  • Stenting and atherectomy
$17,957

 

OBL12 BTK Procedures

CPT‡13DESCRIPTION2025 MEDICARE NAT'L RATE
37228Angioplasty$3,752
37229Atherectomy$8,070
37230Stenting$8,076
37231Stenting and atherectomy$10,596

 

ASC14 Procedures

CPT‡13DESCRIPTION2025 MEDICARE NAT'L RATE
37228Angioplasty$6,603
37229Atherectomy$11,855
37230Stenting$11,439
37231Stenting and atherectomy$12,261

See the Vascular Health Economics and Reimbursement website for additional resources

The material and the information contained herein is for general information purposes only and is not intended, and does not constitute, legal, reimbursement, business, clinical or other advice. Furthermore, it is not intended to and does not constitute a representation or guarantee of reimbursement, payment, or charge, or that reimbursement or other payment will be received. It is not intended to increase or maximize payment by any payer. Abbott makes no express or implied warranty or guaranteed that the list of codes and narratives in this document is complete or error-free. Similarly, nothing in this document should be viewed as instructions for selecting any particular code, and Abbott does not advocate or warrant the appropriateness of the use of any particular code. The ultimate responsibility for coding and obtaining payment/reimbursement remains with the customer. This includes the responsibility for accuracy and veracity of all coding and claims submitted to third-party payers. In addition, the customer should note that laws, regulations, and coverage policies are complex and are updated frequently, and therfore, the customer should check with its local carriers or intermediaries often and should consult with legal counsel or a financial, coding, or reimbursement specialist for any questions related to coding, billing, reimbursement, or any related issues. This material reproduces information for reference purposes only. It is not provided or authorized for marketing use.

Back to top

Sharing Information, Promoting Understanding:

Resources to Help Your Patients Walk Away from PAD/CLTI

Beyond the treatment, make sure your referring physicians are fully aware of PAD and CLTI and how they can help with early diagnosis and timely treatment. For information specifically for the physician, visit our Clear Program webpage. Access a full range of helpful tools and insights. And for your patients, refer them to the PAD-info.com link to support the work you do, so they can learn about PAD symptoms and access an educational brochure.
 


Back to top

RECOMMENDED

Based on the positive results from the LIFE-BTK clinical trial, the EspritTM BTK System real-world performance is being confirmed in the EspritTM BTK post-approval study (PAS). Patients receiving the commercial Esprit BTK product can participate in the EspritTM BTK PAS if they are eligible. Patients can learn more through this website specifically designed for those enrolled or considering enrollment.

About the Esprit BTK PAS Clinical Trial
Esprit BTK PAS Clinical Trial

Back to top

References

  1. Farber, A., Menard, M. T., Bonaca, M. P., Bradbury, A., Conte, M. S., Debus, E. S., ... & Rosenfield, K. (2024). BEST-CLI International Collaborative: planning a better future for patients with chronic limb-threatening ischaemia globally. British Journal of Surgery, 111(2), znad413.
  2. Zeller, T., Rastan, A., Macharzina, R., Pilger, E., Schwarzwälder, U., & Bürgelin, K. (2007). Long-term results after balloon angioplasty of tibial artery obstructions in patients with critical limb ischemia. Journal of Vascular and Interventional Radiology, 18(7), 841-849. doi:10.1016/j.jvir.2007.03.014. Retrieved from https://www.jvir.org/article/S1051-0443(07)00292-5/fulltext00292-5/fulltext).
  3. Varcoe, RL., et al. Drug-Eluting Resorbable Scaffold versus Angioplasty for Infrapopliteal Artery Disease. N Eng J Med 2024;390:9-19.
  4. Esprit™ BTK Everolimus Eluting Resorbable Scaffold System Instructions for Use (IFU). Refer to IFU for additional information.
  5. Data on file at Abbott.
  6. Brian G. DeRubertis et al., Two-Year Outcomes of the LIFE-BTK Randomized Controlled Trial Evaluating the Esprit™ BTK Drug-eluting Resorbable Scaffold for Treatment of Infrapopliteal Lesions, VIVA 2024.
  7. Reintervention defined as CD-TLR.
  8.  Data on file at Abbott. Testing done with XIENCE Sierra™ 3.5 x 38 mm at nominal.
  9. Data on file at Abbott. Excluding platinum markers.
  10. CMS_2025_Hospital Inpatient Prospective Payment-Final Rule Home Page. CMS-1808-F. https://www.cms.gov/medicare/payment/prospective-payment-systems/acute-inpatient-pps/fy-2025-ipps-proposed-rule-home-page.
  11. Hospital Outpatient Prospective Payment- Notice of Final Rulemaking with Comment Period (NFRM) CY2025. CMS 1809-FC. https://www.cms.gov/medicare/payment/prospective-payment-systems/hospital-outpatient/regulations-notices/cms-1809-fc.
  12. Revisions to Payment Policies under the Medicare Physician Fee Schedule, Quality Payment Program and Other Revisions to Part B for CY 2025. CMS-1807-F. https://www.cms.gov/medicare/payment/fee-schedules/physician/federal-regulation-notices/cms-1807-f.
  13. CPT‡ Coding Guidelines. AMA. CPT‡ 2025 Professional Edition. American Medical Association. 2025. https://www.ama-assn.org.
  14. Ambulatory Surgical Center Payment- Notice of Final Rule making with Comment Period (NFRM) CY2025_CMS-1809-FC.

MAT-2403385 v4.0

Important Safety Information
 

Esprit™ BTK Everolimus Eluting Resorbable Scaffold System

rx-only-logo


Indications

The Esprit™ BTK Everolimus Eluting Resorbable Scaffold System is indicated for improving luminal diameter in infrapopliteal lesions in patients with chronic limb-threatening ischemia (CLTI) and total scaffolding length up to 170 mm with a reference vessel diameter of ≥ 2.5 mm and ≤ 4.00 mm.
 

Contraindications

The Esprit™ BTK Everolimus Eluting Resorbable Scaffold System is contraindicated for use in:

  • Patients who cannot tolerate, including allergy or hypersensitivity to, procedural anticoagulation or the post-procedural antiplatelet regimen.
  • Patients with hypersensitivity or contraindication to everolimus or structurally related compounds or known hypersensitivity to scaffold components poly(L-lactide), poly(D, L-lactide), and platinum.
     

Warnings

  • This device is intended for single use only. Do not reuse, reprocess, or re-sterilize. Note the product "Use-by" date on the package. Reuse, reprocessing, or re-sterilization may compromise the structural integrity of the device and / or delivery system and / or lead to device failure, which may result in patient injury, illness, or death. Reuse, reprocessing, or re-sterilization may also create a risk of contamination of the device and / or cause patient infection or cross-infection, including, but not limited to, the transmission of infectious disease(s) from one patient to another. Contamination of the device and / or delivery system may lead to injury, illness, or death of the patient.
  • The Esprit™ BTK System is intended to perform as a system. The scaffold should not be removed for use with other dilatation catheters.
  • The Esprit™ BTK System should not be used in conjunction with other non-everolimus drug eluting devices in the same vessel as the Esprit™ BTK Scaffold.
  • It is not recommended to use this scaffold to treat lesions located at any joint or other hinge points, such as the knee or ankle. The recommended region for below-the-knee (BTK) treatment with the Esprit™ BTK Scaffold is the infrapopliteal arteries at a location ≥ 10 cm above the proximal margin of the ankle mortise. The Esprit™ BTK Scaffold has not been tested for use outside the recommended implant locations.
  • This product should not be used in patients with aneurysms immediately adjacent to the scaffold implantation site.
  • Insertion of the Esprit™ BTK System and implantation of the scaffold should be performed only under fluoroscopic observation with radiographic equipment providing high resolution images.
  • Quantitative imaging is strongly recommended to accurately measure and confirm appropriate vessel sizing (reference vessel diameter ≥ 2.5 mm). If quantitative imaging determines a vessel size < 2.5 mm, do not implant the Esprit™ BTK scaffold.
  • Adequate lesion preparation prior to scaffold implantation is required to ensure safe delivery of the scaffold across the target lesion. It is not recommended to treat patients having a lesion that prevents complete inflation of an angioplasty balloon.
  • Successful pre-dilatation with residual diameter stenosis of < 30% by visual estimation is required for treatment of the target lesion; < 20% by visual estimation is preferred.
  • Ensure the scaffold is not post-dilated beyond the allowable expansion limits.
  • Use of appropriate anticoagulant and / or antiplatelet therapy per standard of care is recommended for use of this scaffold system.
  • This product should not be used in patients who are not likely to comply with the recommended antiplatelet therapy.
  • Judicious selection of patients is necessary, since the use of this device carries the associated risk of scaffold thrombosis, vascular complications, and / or bleeding events.
     

Precautions

  • Scaffold placement should not be performed in patients with known allergies to contrast agent that cannot be medically managed.
  • It is not recommended to treat patients having a lesion with excessive tortuosity proximal to or within the lesion.
  • When multiple scaffolds are required, only combinations of Esprit™ BTK Scaffolds must be used. Any potential interaction with other drug-eluting or coated devices has not been evaluated.
  • The delivery system is intended for deployment of the scaffold only and should not be used to dilate other locations.
  • Implantation of the scaffold should be performed only by physicians who have received appropriate training.
  • As with all catheter-based procedures, scaffold placement should be performed at facilities where patient can be prepared for necessary intervention and / or surgical removal of the device and vessel repair as per facility protocol.
  • Pre-dilatation should be performed with an angioplasty balloon. Cutting or scoring balloons can be used per physician discretion, if the lesion appears to be mildly calcified.
  • Failure to pre-dilate the vessel may impair nominal / optimal scaffold delivery.
  • Implanting a scaffold may lead to dissection of the vessel distal and / or proximal to the scaffold, requiring additional intervention.

    Note: In cases of bailouts, bailout treatment of the target lesion can be done using the Esprit™ BTK Scaffold of the appropriate length. If an appropriate length Esprit™ BTK Scaffold is not available, physicians should use standard of care.
  • An unexpanded scaffold may be retracted into the introducer sheath one time only. An unexpanded scaffold should not be reintroduced into the artery once it has been pulled back into the introducer sheath.
  • Post-dilatation is strongly recommended for optimal scaffold apposition. When performed, post-dilatation should be performed at high pressure (> 16 atm) with a non-compliant balloon up to 0.5 mm larger than the nominal scaffold diameter.
  • Use an appropriately sized non-drug coated balloon to pre-dilate the lesion. When treating a long lesion, scaffold the distal portion of the lesion prior to scaffolding the proximal portion of the lesion.
  • Ensure that the scaffolded area covers the entire lesion / dissection site and that no gaps exist between scaffolds.
  • The extent of the patient’s exposure to drug and polymer is directly related to the number of scaffolds implanted. The safety of everolimus, polymer, and polymer breakdown products was evaluated in pre-clinical studies and the biocompatibility assessment of the Esprit™ BTK Scaffold.
  • The safety and effectiveness of the Esprit™ BTK Scaffold in patients with prior brachytherapy of the target lesion or the use of brachytherapy for treated-site restenosis in the Esprit™ BTK Scaffold have not been established. Both vascular brachytherapy and the Esprit™ BTK Scaffold alter arterial modeling. The potential combined effect on arterial remodeling by these two treatments is not known.
  • The safety and effectiveness of the Esprit™ BTK System have not been established in clinical trials with the use of either mechanical atherectomy devices (directional atherectomy catheters, rotational atherectomy catheters) or laser atherectomy catheters.
  • Formal drug interaction studies have not been performed with the Esprit™ BTK Scaffold because of limited exposure to everolimus eluted from the scaffold.
  • Everolimus, the Esprit™ BTK Scaffold’s active pharmaceutical ingredient, is an immunosuppressive agent. Therefore, consideration should be given to patients taking other immunosuppressive agents or who are at risk for immune suppression.
  • Oral everolimus use in renal transplant and advanced renal cell carcinoma patients was associated with increased serum cholesterol and triglyceride levels, which in some cases required treatment.
  • Non-clinical testing has demonstrated the Esprit™ BTK Scaffold is MR Conditional. A person with the Esprit™ BTK Scaffold may be safely scanned under the following conditions. Failure to follow these conditions may result in injury
    • Static magnetic field strength of 7 Tesla or less
  • The Esprit™ BTK Scaffold should not migrate in this MRI environment. MRI at 7 Tesla or less may be performed immediately following the implantation of the Esprit™ BTK Scaffold.
     

Potential Adverse Events

Potential adverse events include, but are not limited to:

Allergic reaction or hypersensitivity to contrast agent, anesthesia, scaffold materials (poly[L-lactide] [PLLA], poly[D, L-lactide] [PDLLA], platinum, or everolimus), and drug reactions to anticoagulation or antiplatelet drugs

  • Vascular access complications which may require transfusion or vessel repair, including:
    • Catheter site reactions
    • Bleeding (ecchymosis, oozing, hematoma, hemorrhage, retroperitoneal hemorrhage)
    • Arteriovenous fistula, pseudoaneurysm, aneurysm, dissection, perforation / rupture, and laceration
    • Embolism (air, tissue, plaque, thrombotic material, or device)
    • Peripheral ischemia
  • Target artery complications which may require additional intervention, including:
    • Total occlusion or abrupt closure
    • Arteriovenous fistula, pseudoaneurysm, aneurysm, dissection, perforation / rupture
    • Embolism (air, tissue, plaque, thrombotic material, or device)
    • Artery or scaffold thrombosis
    • Stenosis or restenosis
    • Vasospasm
    • Tissue prolapse / plaque shift
  • Bleeding (non-access site)
  • Additional surgery such as peripheral artery bypass graft surgery or amputation
  • Peripheral nerve injury, neuropathy
  • Compartment syndrome
  • Tissue necrosis, gangrene, ulcer and acute limb ischemia
  • Reperfusion injury
  • New or worsening pain
  • Intervention due to
    • Damaged scaffolds
    • Partial scaffold deployment
    • Scaffold migration / unintentional placement of scaffold
  • Other general surgical risks, including:
    • Cardiac arrhythmias (including conduction disorders, atrial and ventricular arrhythmias, and blocks)
    • Stroke / cerebrovascular accident (CVA) and transient ischemic attack (TIA)
    • Venous thromboembolism (including pulmonary embolism)
    • Nausea and vomiting
    • Hypotension / hypertension
    • Infection – local and systemic (including post-procedural)
    • Fever
    • Blood cell disorders including heparin induced thrombocytopenia (HIT) and other coagulopathy
    • Death
  • System organ failures:
    • Cardiac Failure
    • Cardio-respiratory arrest (including pulmonary edema)
    • Respiratory failure
    • Renal failure
    • Shock

The risks described below include the anticipated adverse events referenced in the contraindications, warnings, and precautions sections of the everolimus labels / SmPCs and / or observed at incidences ≥ 10% in clinical trials with oral everolimus for different indications. Refer to the drug SmPCs and labels for more detailed information and less frequent adverse events.

  • Abdominal pain
  • Anemia
  • Angioedema (increased risk with concomitant angiotensin converting enzyme [ACE] inhibitor use)
  • Arterial thrombotic events
  • Bleeding and coagulopathy (including hemolytic uremic syndrome [HUS], thrombotic thrombocytopenic purpura [TTP], and thrombotic microangiopathy; increased risk with concomitant cyclosporine use)
  • Constipation
  • Cough
  • Diabetes mellitus
  • Diarrhea
  • Dyspnea
  • Embryo-fetal toxicity
  • Erythema
  • Erythroderma
  • Headache
  • Hepatic artery thrombosis (HAT)
  • Hepatic disorders (including hepatitis and jaundice)
  • Hypersensitivity to everolimus active substance, or to other rapamycin derivates
  • Hypertension
  • Infections (bacterial, viral, fungal, or protozoan infections, including infections with opportunistic pathogens). Polyoma virus-associated nephropathy (PVAN), JC virus associated progressive multiple leukoencephalopathy (PML), fatal infections and sepsis have been reported in patients treated with oral everolimus.
  • Kidney arterial and venous thrombosis
  • Laboratory test alterations (elevations of serum creatinine, proteinuria, hypokalemia, hyperkalemia; hyperglycemia, dyslipidemia including hypercholesterolemia and hypertriglyceridemia; abnormal liver function tests; decreases in hemoglobin, lymphocytes, neutrophils, and platelets)
  • Lymphoma and skin cancer
  • Male infertility
  • Menstrual irregularities
  • Nausea
  • Nephrotoxicity (in combination with cyclosporine)
  • Non-infectious pneumonitis (including interstitial lung disease)
  • Oral ulcerations
  • Pain
  • Pancreatitis
  • Pericardial effusion
  • Peripheral edema
  • Pleural effusion
  • Pneumonia
  • Pyrexia
  • Rash
  • Renal failure
  • Upper respiratory tract infection
  • Urinary tract infection
  • Venous thromboembolism
  • Vomiting
  • Wound healing complications (including wound infections and lymphocele)

There may be other potential adverse events that are unforeseen at this time.

MAT-2403616 v1.0

POLICIES & ADVISORIES
HEALTHCARE PROFESSIONALS
PATIENTS & CAREGIVERS
abbott logo

CAUTION: These products are intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use, inside the product carton (when available) or online for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events.

Illustrations are artist's representations only and should not be considered as engineering drawings or photographs.

Unless otherwise specified, all product names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company. ™ Indicates a trademark of the Abbott group of companies. ‡ Indicates a third party trademark, which is property of its respective owner.

© 2025 Abbott. All Rights Reserved.

MAT-1900882 v14.0